A la une

  1. Nouvel article de l'équipe cytosquelette et neurophysiopathologie

    Le dernier travail de l'équipe 9 de l'INP : "Tau regulates the microtubule-dependent migration of glioblastoma cells via the Rho-ROCK signaling pathway" est maintenant publié dans J. cell. Science. Ces travaux identifient pour la première fois le rôle et les mécanismes impliquant la proteine tau dans les processus d'invasion des glioblastomes, tumeurs cérébrales très agressives. Ces travaux soulignent le rôle de la protéine Tau comme une cible commune entre les cancers et la neurodégénératio

  2. Hervé Kovacic élu président du CNU section 85

    Professeur de Biophysique et Biomathématique à la Faculté de Pharmacie de Marseille, Hervé Kovacic est élu pour un mandat de six ans. La section CNU 85 gère les qualifications, promotions et primes des enseignant-chercheurs spécialisés en sciences physico-chimiques et ingénierie appliquée à la santé. Docteur Pascale Barbier, elle aussi membre de l'équipe 9 de l'INP a été nominé par le Ministère dans la même section CNU.

  3. Jean-Michel Paumier successfully defended his doctoral thesis

    Jean-Michel Paumier, former PhD student in Team 1 (Neural Plasticity and Degeneration), has successfuly defended his thesis on Wednesday the 05th of December 2018. After few hours of a nice presentation followed by many questions, the examining board congratulated Jean-Michel for his good work and granted him the diploma of doctor in Neuroscience.

  4. Vect-Horus announces agreement with Johnson & Johnson innovation

    Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The goal of this collaboration is to use Vect-Horus’ proprietary technology to transport various Janssen monoclonal antibodies to the brain for the treatment of neurodegenerative diseases. This deal was facilitated by Johnson & Johnson Innovation Limited.

  5. Santiago Rivera gave two conferences on Alzheimer's disease

    The first conference entitled “Alzheimer’s disease, fears and hopes” was given at the meeting of the management boards of the french Vaincre l’Alzheimer and the german Alzheimer Forschung Initiative foundations that was held on November 16th 2018 at the Novotel Hotel Marseille Vieux Port.

    The second conference, in the context of the Conferences Cycle of the Institute of Neurosciences of the University of Barcelona, was entitled “ Membrane type-matrix metalloproteinases are newcomers to the Alzheimer’s field ”  ans was held on November 20th at the School of Pharmacy of the University of Barcelona.

  6. New article from the Neural Degeneration and Plasticity team

    The latest work from the Neural Degeneration and Plasticity team, in collaboration with the BBB and neuroinflammation team of Michel Khrestchatisky: "The pro-amyloidogenic effects of Membrane-type 1-Matrix Metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking" is now published in the FASEB Journal (doi: 10.1096/fj.201801076R). Our data unveil new mechanistic insights supporting the pro-amyloidogenic role of MT1-MMP based on APP processing and trafficking, and reinforces the idea that MT1-MMP may become a new potential therapeutic target in Alzheimer’s disease. 

  7. 6th French Biacore User Meeting

    Géraldine Ferracci, manager of the Surface Plasmon Resonance unit at INP's Plateform Interactome Neuro-Timone (PINT), gave a talk at the 6th Biacore Users' Meeting. During her presentation untitled "Contribution of the SPR in the study of membrane proteins: from their quantification to the optimization of therapeutic peptide vectors", she stressed the role of this major biophysical technique, played in the therapeutic approaches developed within the INP.

  8. Yvon Berland and Alexandre Tokay, respectively President of AMU and CEO of Vect-Horus signed a Public-Private Partnership allowing Vect-Horus to settle its research activities in the La Timone Medical Faculty

    Vect-Horus has established a long-term highly efficient collaboration with the Institute of NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, and this Partnership signed on November 14, 2018 is a cornerstone in the creation of the LABCOM (Common Research Lab) between the INP and Vect-Horus.

Pages

L'INP en chiffres

  • 126 membres
  • 44 chercheurs
  • 48 chercheurs assistants
  • 12 post-doctorants
  • 11 doctorants

 

Nouvel article de l'équipe cytosquelette et neurophysiopathologie

Le dernier travail de l'équipe 9 de l'INP : "Tau regulates the microtubule-dependent migration of glioblastoma cells via the Rho-ROCK signaling pathway" est maintenant publié dans J. cell. Science. Ces travaux identifient pour la première fois le rôle et les mécanismes impliquant la proteine tau dans les processus d'invasion des glioblastomes, tumeurs cérébrales très agressives. Ces travaux soulignent le rôle de la protéine Tau comme une cible commune entre les cancers et la neurodégénératio

Français

Hervé Kovacic élu président du CNU section 85

Professeur de Biophysique et Biomathématique à la Faculté de Pharmacie de Marseille, Hervé Kovacic est élu pour un mandat de six ans. La section CNU 85 gère les qualifications, promotions et primes des enseignant-chercheurs spécialisés en sciences physico-chimiques et ingénierie appliquée à la santé. Docteur Pascale Barbier, elle aussi membre de l'équipe 9 de l'INP a été nominé par le Ministère dans la même section CNU.

Français

Jean-Michel Paumier successfully defended his doctoral thesis

Jean-Michel Paumier, former PhD student in Team 1 (Neural Plasticity and Degeneration), has successfuly defended his thesis on Wednesday the 05th of December 2018. After few hours of a nice presentation followed by many questions, the examining board congratulated Jean-Michel for his good work and granted him the diploma of doctor in Neuroscience.

Indéfini

Vect-Horus announces agreement with Johnson & Johnson innovation

Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The goal of this collaboration is to use Vect-Horus’ proprietary technology to transport various Janssen monoclonal antibodies to the brain for the treatment of neurodegenerative diseases. This deal was facilitated by Johnson & Johnson Innovation Limited.

Indéfini

New article from the Neural Degeneration and Plasticity team

The latest work from the Neural Degeneration and Plasticity team, in collaboration with the BBB and neuroinflammation team of Michel Khrestchatisky: "The pro-amyloidogenic effects of Membrane-type 1-Matrix Metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking" is now published in the FASEB Journal (doi: 10.1096/fj.201801076R).

Indéfini

Yvon Berland and Alexandre Tokay, respectively President of AMU and CEO of Vect-Horus signed a Public-Private Partnership allowing Vect-Horus to settle its research activities in the La Timone Medical Faculty

Vect-Horus has established a long-term highly efficient collaboration with the Institute of NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, and this Partnership signed on November 14, 2018 is a cornerstone in the creation of the LABCOM (Common Research Lab) between the INP and Vect-Horus.

Indéfini

Agenda

1 mar 2019 14:30

Team 9 - Cytoskeleton and Neurophysiopathology

Faculté de pharmacie de la Timone

 

This seminar will be followed by a presentation by Protisvalor on the H2020 projects.

8 mar 2019 14:30

Team 8 - GlioME: Gliomagenesis and MicroEnvironment

Faculté de médecine Nord, salle de conférences, bâtiment E

Partenaires